The trend of NCAD expressions in Silverberg–Shimizu grades is similar to the WHO tumour Types, where benign tissue expression is higher than early grade/Type I tumours, then NCAD expression increases with disease grade, such that grade 3/Type II tumours have higher expression than grade 1/Type I tumours (Figure 5b). The gene discussed is CDH2; the disease is neoplasm.